Aclaris Therapeutics, Inc.

Informe acción NasdaqGS:ACRS

Capitalización de mercado: US$271.4m

Aclaris Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de Aclaris Therapeutics es Neal Walker, nombrado en Jul 2012, tiene una permanencia de 12.33 años. posee directamente un 1.93% de las acciones de la empresa, con un valor de $5.23M. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 10.5 años, respectivamente.

Información clave

Neal Walker

Chief Executive Officer (CEO)

US$73.5k

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO12.3yrs
Participación del CEO1.9%
Permanencia media de la dirección1.8yrs
Promedio de permanencia en la Junta Directiva10.5yrs

Actualizaciones recientes de la dirección

Recent updates

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 12
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

Aug 08
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

May 03
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Mar 07
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Mar 01
Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 19
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 11
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Nov 03
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

Aug 10
Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Aug 08
What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Jun 06
Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions

Oct 06

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata

Aug 25

Aclaris Therapeutics gets a new COO

Aug 01

Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

May 28
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Dec 14
We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Neal Walker en comparación con los beneficios de Aclaris Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

-US$37m

Jun 30 2024n/an/a

-US$59m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$74kn/a

-US$88m

Sep 30 2023n/an/a

-US$115m

Jun 30 2023n/an/a

-US$105m

Mar 31 2023n/an/a

-US$96m

Dec 31 2022US$6mUS$590k

-US$87m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$7mUS$567k

-US$91m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021n/an/a

-US$71m

Mar 31 2021n/an/a

-US$65m

Dec 31 2020US$2mUS$424k

-US$51m

Sep 30 2020n/an/a

-US$57m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$102m

Dec 31 2019US$3mUS$500k

-US$114m

Sep 30 2019n/an/a

-US$118m

Jun 30 2019n/an/a

-US$115m

Mar 31 2019n/an/a

-US$79m

Dec 31 2018US$4mUS$550k

-US$82m

Sep 30 2018n/an/a

-US$81m

Jun 30 2018n/an/a

-US$79m

Mar 31 2018n/an/a

-US$86m

Dec 31 2017US$810kUS$510k

-US$50m

Compensación vs. Mercado: La compensación total de Neal($USD73.50K) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD1.46M).

Compensación vs. Ingresos: La compensación de Neal ha sido consistente con los resultados de la empresa en el último año.


CEO

Neal Walker (54 yo)

12.3yrs

Permanencia

US$73,500

Compensación

Dr. Neal S. Walker, D.O. & M.D., is Venture Partner of Forge Life Science Partners. He Co-founded Aclaris Therapeutics, Inc. in 2012 and has been its Director since July 2012 and serves as its Chairman sin...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Neal Walker
Co-Founder12.3yrsUS$73.50k1.93%
$ 5.2m
Kevin Balthaser
Chief Financial Officer1.8yrsUS$2.34m0.035%
$ 93.8k
Joseph Monahan
Chief Scientific Officer3.8yrsUS$2.26m0.26%
$ 710.5k
James Loerop
Chief Business Officer2.8yrsUS$2.33m0.048%
$ 129.3k
Hugh M. Davis
President & COOno datasin datossin datos
Matthew Rothman
General Counsel & Corporate Secretary2.4yrssin datossin datos
Jon Jacobsen
Senior Vice President of Chemistryno datasin datossin datos
Steve Tucker
Senior Vice President of Project Leadershipless than a yearsin datossin datos
Ajay Aggarwal
Senior Vice President of Clinical Developmentless than a yearsin datossin datos
Steven Knapp
Executive Vice Presidentno datasin datossin datos

1.8yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ACRS no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Neal Walker
Co-Founder12.3yrsUS$73.50k1.93%
$ 5.2m
Vincent Milano
Independent Director4.8yrsUS$180.38k0.018%
$ 47.6k
Mark Bradshaw
Member of Advisory Boardno datasin datossin datos
James Leyden
Member of Advisory Boardno datasin datossin datos
Klaus Theobald
Member of Advisory Boardno datasin datossin datos
Anand Mehra
Independent Director10.2yrsUS$194.38k0.99%
$ 2.7m
Pearl Grimes
Member of Advisory Boardno datasin datossin datos
Guy Webster
Member of Advisory Boardno datasin datossin datos
Christopher Molineaux
Lead Independent Director10.8yrsUS$206.88k0.074%
$ 202.0k
Kenneth Beer
Member of Advisory Boardno datasin datossin datos
Leslie Baumann
Member of Advisory Boardno datasin datossin datos
Andrew Ondo
Member of Advisory Boardno datasin datossin datos

10.5yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de ACRS son experimentados ( 10.5 años antigüedad media).